Defence Therapeutics Initiates Lung Cancer Treatment Program with Its Novel AccuTOX(TM) Formulation via Intranasal
Vancouver, British Columbia--(Newsfile Corp. - October 12, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the start of a pre-clinical program using its novel patent pending technology AccuTOXTM. The novel AccuTOXTM formulation is designed for the treatment of lung cancer including various...
2022-10-12 3:15 AM EDT
Defence Therapeutics Is Granted Patents in Japan and Israel Expanding Its Novel ADC Platform Technology in the Fast Growing Antibody-Drug Conjugates Market
Vancouver, British Columbia--(Newsfile Corp. - September 29, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugate ("ADC"), is pleased to announce that a notice of allowance has been issued by the Japan Patent Office for its Japanese patent application no. 2018-568469. In...
2022-09-29 3:15 AM EDT
Breakthrough Results with Accum(TM) A1-Reprogrammed MSC, Mesenchymal Stem Cells, in a Novel Vaccine Cured 80% of Animals with Pre-Established Lymphoma
Vancouver, British Columbia--(Newsfile Corp. - September 21, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report that Defence's novel vaccine candidate triggers a potent anti-tumoral response capable of curing animals with pre-established lymphoma. Antigen presentation is a crucial step for the...
2022-09-21 3:15 AM EDT
Defence Therapeutics Applauds United States President Biden Cancer Moonshot Initiative
Vancouver, British Columbia--(Newsfile Corp. - September 16, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biotech company actively working on accelerating scientific discoveries and products development against cancer, congratulates the US President Joe Biden for the executive order signed on Monday establishing the Biotechnology and Biomanufacturing initiative to ensure cutting-edge biotechnologies necessary to end cancer...
2022-09-16 2:00 PM EDT
Breakthrough Discovery: Defence's Accum(TM) Variant "A1" Converts Mesenchymal Stromal Cells into Potent Antigen Presenting Cells Suitable for Cancer Vaccination
Vancouver, British Columbia--(Newsfile Corp. - August 17, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the development of a novel anti-cancer cellular vaccine by reprogramming the unconventional suppressive mesenchymal stromal cells (MSCs) into potent antigen presenting cells (APCs). The...
2022-08-17 3:15 AM EDT
Defence Therapeutics Receives U.S. Patent Covering Its ADC Platform Technology
Vancouver, British Columbia--(Newsfile Corp. - August 8, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugate ("ADC"), is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted Defence Therapeutics Inc. the U.S. patent no. 11,352,437....
2022-08-08 3:15 AM EDT
Breakthrough Discovery: AccuTOX(TM) Effectively Kills Cancer Cells by Directly Eliciting DNA Damage
Vancouver, British Columbia--(Newsfile Corp. - August 2, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the discovery of a novel DNA damaging function triggered by one of its lead compounds AccuTOXTM, which effectively elicits cell death in cancer cells. Cancer can be generally described as...
2022-08-02 3:15 AM EDT
Defence's Accum(TM) with Antibody Drug Conjugates (ADC) in Development Against Cancer
Vancouver, British Columbia--(Newsfile Corp. - July 5, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to provide an update on its ADC programs in development using Defence's AccumTM, including key in vivo studies with worldwide collaborators. The world-renowned Curie Institute, one of Defence's...
2022-07-05 3:15 AM EDT
Defence Reports Effective Control of Cervical Cancer Growth in Response to Its AccuVAC-PT007 Therapeutic Vaccination
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report potent pre-clinical results on the use of its AccumTM-linked protein vaccine, AccuVAC-PT007, against cervical cancer. Cervical cancer is a type of cancer affecting the cervix. Various...
2022-06-27 3:15 AM EDT
RETRANSMISSION: Defence's Novel AccuVAC-PTE7 Vaccine Shows Complete Protection from Cervical Cancer
Vancouver, British Columbia--(Newsfile Corp. - May 18, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focused on the development of novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the development of novel dual-acting AccumTM-linked protein vaccine, AccuVAC-PTE7, dedicated to protect from cervical cancer (prophylactic vaccine) or to treat (therapeutic...
2022-05-18 11:30 AM EDT
Defence Novel AccuVAC-PTE7 Vaccine Shows Complete Protection from Cervical Cancer
Vancouver, British Columbia--(Newsfile Corp. - May 17, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the development of novel dual-acting AccumTM-linked protein vaccine, AccuVAC-PTE7, dedicated to protect from cervical cancer (prophylactic vaccine) or to treat (therapeutic...
2022-05-17 4:30 PM EDT
Defence Therapeutics Announces Issuance Of a U.S. Patent Covering Its Pioneering Vaccine Platform Technology
Vancouver, British Columbia--(Newsfile Corp. - April 7, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company primarily focused on the development of novel vaccines and drug delivery technologies, is pleased to announced that the United States Patent and Trademark Office (USPTO) has granted patent number US 11,291,717 ('717) covering its breakthrough vaccine platform technology for the treatment/prevention...
2022-04-07 3:15 AM EDT
Defence Therapeutics: An Anti-Cancer Solutions Platform Company Advancing Its Versatile Accum Technology
Vancouver, British Columbia--(Newsfile Corp. - March 22, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF)("Defence" or the "Company"), a Canadian biotech company actively working on accelerating scientific discoveries and products development against cancer, is pleased to provide an overview of its current research and development progress in various cancer activities. In Q1 of 2022, Defence has signed an agreement with the Advanced Therapies Facilities (ATF) - GMP...
2022-03-22 3:15 AM EDT
Defence Releases Peer-Reviewed Publication of Its Preclinical Data on AccuVAC-D001L In Cell Reports Medicine Journal
Vancouver, British Columbia--(Newsfile Corp. - February 28, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a pre-clinical biotechnology company developing various products for the immune-oncology space, is pleased to announce the publication of its first peer-reviewed study on the potency of AccuVAC-D001L. AccuVAC-D001L is one of Defence's dendritic cell (DC) vaccine products designed to treat established T-cell lymphoma developed from...
2022-02-28 3:15 AM EST
Defence Retains CATO SMS to Advise on Its Phase I Clinical Trial on AccuTOX(TM) for Breast Cancer
Vancouver, British Columbia--(Newsfile Corp. - February 16, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a pre-clinical biotechnology company developing various products for the immune-oncology space, is pleased to announce the establishment of an agreement with CATO SMS, to advise on the submission of its clinical application to Health Canada in order to initiate a Phase I trial using AccuTOXTM against breast cancer. CATO SMS is a...
2022-02-16 3:15 AM EST
Defence's Accum(TM)-HPV Vaccine Formulation (AccuVAC-PT009) Activates a 36-Fold Higher Humoral Response Compared to Gardasil-9
Vancouver, British Columbia--(Newsfile Corp. - January 26, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a pre-clinical biotechnology company developing various immune-oncology products, is pleased to announce the development of AccuVAC-PT009, a new protein-based HPV vaccine, leading to a humoral response bypassing Gardasil-9 (Merck) immunogenicity in animals. ACCUMTM is a platform technology 100% owned by Defence Therapeutics. ACCUMTM...
2022-01-26 3:15 AM EST
Defence Therapeutics Achieves a Major Milestone and Begins IND-Enabling Testing of Its AccuTOX Lead Compound Against Breast Cancer
Vancouver, British Columbia--(Newsfile Corp. - January 10, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a pre-clinical biotechnology company developing various immune-oncology products, is pleased to announce the start of its final step in GLP studies on its lead anti-cancer AccuTOXTM molecule at Eurofins Advinus Limited prior to initiate its Phase I trial in breast cancer patients. Eurofins Advinus Limited is a leading Drug Discovery...
2022-01-10 3:15 AM EST
Defence Therapeutics Accum(TM) Boosts by 9-Fold the Delivery Effectiveness of the CRISPR/Cas9 Protein to Target Cells
Vancouver, British Columbia--(Newsfile Corp. - December 13, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company focused on the development of vaccines and therapeutics against cancer and infectious diseases, is pleased to announce that its AccumTM platform can potently enhance Cas9 delivery in target cells, which would have a significant positive impact on the CRISPR industry. The CRISPR technology offers the...
2021-12-13 3:15 AM EST
Defence Therapeutics Vaccines and Program Development
Vancouver, British Columbia--(Newsfile Corp. - November 30, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), is a publicly-traded biotechnology company working on engineering the next generation vaccines, Antibody Drug Conjugates, ADC products, and cancer therapeutics using its proprietary AccumTM platform. The core of Defence Therapeutics platform is its AccumTM technology, which enables precision delivery of proteins of pharmacological...
2021-11-30 3:15 AM EST
Defence Therapeutics Cancer Vaccine AccuVac-D001 Manufacturing Targets Melanoma and Breast Cancer
Vancouver, British Columbia--(Newsfile Corp. - November 23, 2021) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines is pleased to announce the establishment of an agreement with the Lady Davis Institute cell processing center (CPC) to initiate manufacturing of its AccumTM DC cancer vaccine candidate AccuVAC-D001. This agreement immediately positions Defence's...
2021-11-23 3:15 AM EST